Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Savara Inc.
Headquarters: Austin, TX, United States of America
Website: http://savarapharma.com
Year Founded: 2007
Status: Public
Industry Sector: HealthTechnology
CEO: Matthew Pauls, MBA
Number Of Employees: 37
Enterprise Value: $640,880,864
PE Ratio: -6.31
Exchange/Ticker 1: NASDAQ:SVRA
Exchange/Ticker 2: N/A
Latest Market Cap: $473,668,384
BioCentury | Jul 3, 2024
Product Development
Clinical Report: Updates in myasthenia gravis from J&J, Cartesian
Plus: Readouts for Savara, Lyell and Novo Nordisk
BioCentury | Jun 29, 2024
Finance
Public Equity Report: Alumis slides after downsized IPO
Plus: Offerings by Zealand, Savara and Taysha; Savara’s PIPE; Grail reaches NASDAQ after Illumina separation
BioCentury | Aug 3, 2023
Data Byte
July follow-on financings: argenx raised majority of month’s $2.1B total
Ten biopharmas raised a combined $2.1B in July, of which argenx was responsible for nearly $1.3B
BioCentury | Feb 16, 2023
Management Tracks
Chinook names Oxtoby head of commercial
Plus: Asabys promotes two to partner and updates from Savara, TriNetX, Mahana, Curi Bio and more
BioCentury | Nov 14, 2022
Data Byte
A snapshot of the GM-CSF pipeline
GSK’s decision to drop otilimab brings other GM-CSF therapies under focus
BioCentury | Aug 26, 2022
Management Tracks
Leading China biotechs Everest, CStone announce CEO departures
Plus updates from BD, Sema4,
BioCentury | Dec 2, 2021
Management Tracks
Maraganore headlines Arch’s latest crop of venture partners
Plus Five FDA vets join Sidley and updates from AZ, Neurocrine, ADCendo, Ironwood and more
BioCentury | Sep 12, 2020
Management Tracks
New CEO Hirsch to guide C4 onto NASDAQ; plus Biller adds CFO title at Agios and updates from Sherlock, Lumen and more
It’s been a busy week for C4 Therapeutics Inc., which hired a new CEO and filed to go public. Andrew Hirsch is joining the protein degradation company from Agios
BioCentury | Nov 20, 2019
Company News
Management tracks: Vifor, Relay, I-Mab, Yumanity, Savara and more
BioCentury | Jun 14, 2019
Clinical News
June 13 Clinical Quick Takes: Roche's Gazyva meets in Phase II for lupus; plus Boehringer/Lilly, Savara and more
Items per page:
1 - 10 of 27